We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina Offers FDA-Approved NGS Cancer Companion Test Kit
Read MoreHide Full Article
Global leader in the field of DNA sequencing and array-based technologies, Illumina, Inc. (ILMN - Free Report) recently announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines. This new kit fulfills the most up-to-date guidance for RAS testing to determine eligibility of epidermal growth factor receptor (EGFR) inhibitors in metastatic colorectal cancer. This product also offers extended gene coverage that implies the simultaneous detection of 56 RAS mutations contraindicated for anti-EGFR therapy. This product also helps in Integrated Workflow by providing comprehensive diagnostic solution which includes library prep, sequencing and clinical report.
This Extended RAS Panel kit is intended to be used on the Illumina MiSeqDx System to detect patients who are eligible for metastatic colorectal cancer treatment with Vectibix. Notably, Vectibix represents an innovative treatment option for first-line treatment for patients with wild-type RAS metastatic colorectal cancer (mCRC).
Per management, the Extended RAS Panel paves the way for broader-based genomics solutions as a first companion diagnostic and Pre-Market Application (PMA) approval in Oncology. The shipment of this kit will start in the third quarter of 2017.
According to Markets and Markets, the global next-generation sequencing market is estimated to reach a worth of $12.45 billion by 2022, at a CAGR of 20.5%.
For the majority of the past one year, Illumina has been trading above the Zacks categorized Medical - Biomedical And Geneticsindustry. The company has gained 23.3%, when compared to the 1.5% gain of the broader industry.
Recent Developments
Illumina recently announced the launch of a solution under its noninvasive prenatal testing (NIPT) kit in Europe. VeriSeq NIPT solution is a CE-IVD marked next-generation sequencing (NGS)-based approach to NIPT. The solution helps laboratories screen accurate information about fetal chromosome status as early as one day.
Zacks Rank & Key Picks
Illumina currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Align Technology and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 29.9% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 24.4% over the last three months.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has added roughly 9.8% over the last three months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Illumina Offers FDA-Approved NGS Cancer Companion Test Kit
Global leader in the field of DNA sequencing and array-based technologies, Illumina, Inc. (ILMN - Free Report) recently announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines. This new kit fulfills the most up-to-date guidance for RAS testing to determine eligibility of epidermal growth factor receptor (EGFR) inhibitors in metastatic colorectal cancer. This product also offers extended gene coverage that implies the simultaneous detection of 56 RAS mutations contraindicated for anti-EGFR therapy. This product also helps in Integrated Workflow by providing comprehensive diagnostic solution which includes library prep, sequencing and clinical report.
This Extended RAS Panel kit is intended to be used on the Illumina MiSeqDx System to detect patients who are eligible for metastatic colorectal cancer treatment with Vectibix. Notably, Vectibix represents an innovative treatment option for first-line treatment for patients with wild-type RAS metastatic colorectal cancer (mCRC).
Per management, the Extended RAS Panel paves the way for broader-based genomics solutions as a first companion diagnostic and Pre-Market Application (PMA) approval in Oncology. The shipment of this kit will start in the third quarter of 2017.
According to Markets and Markets, the global next-generation sequencing market is estimated to reach a worth of $12.45 billion by 2022, at a CAGR of 20.5%.
For the majority of the past one year, Illumina has been trading above the Zacks categorized Medical - Biomedical And Geneticsindustry. The company has gained 23.3%, when compared to the 1.5% gain of the broader industry.
Recent Developments
Illumina recently announced the launch of a solution under its noninvasive prenatal testing (NIPT) kit in Europe. VeriSeq NIPT solution is a CE-IVD marked next-generation sequencing (NGS)-based approach to NIPT. The solution helps laboratories screen accurate information about fetal chromosome status as early as one day.
Zacks Rank & Key Picks
Illumina currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Align Technology and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 29.9% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 24.4% over the last three months.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has added roughly 9.8% over the last three months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>